CAR-engineering of innate and innate-like immune cells: a new horizon in adoptive cell therapy for solid tumors
Background
Chimeric antigen receptor (CAR) therapies have revolutionized cancer immunotherapy, particularly in hematologic malignancies, but their efficacy in solid tumors remains limited. Key barriers include tumor antigen heterogeneity, on-target/of…